IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES: BRAFV600E Expression in Melanoma Cases

Muhammad Umer Ch; Farhan Akhtar; Nighat Jamal; Rabia Ahmad; Sumaira Bukhsh; Hamza Mansur

doi:10.51253/pafmj.v71i5.5955

Authors

Muhammad Umer Ch Pakistan Naval Ship Shifa Hospital, Karachi Pakistan
Farhan Akhtar Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Nighat Jamal Pakistan Naval Ship Shifa Hospital, Karachi Pakistan
Rabia Ahmad Pakistan Naval Ship Shifa Hospital, Karachi Pakistan
Sumaira Bukhsh Combined Military Hospital Malir/National University of Medical Sciences (NUMS) Pakistan
Hamza Mansur Armed Forces Institute of Pathology/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v71i5.5955

Keywords:

BRAFV600E mutation, Immunohistochemistry, Monoclonal antibody, Malignant melanoma

Abstract

Objective: To evaluate the diagnostic value of Immunohistochemistry (IHC) for finding BRAFV600E mutation in melanoma patients.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, Jan 2018 to Apr 2019.

Methodology: Hundred histologically confirmed cases of melanoma aged between 18-80 years were included over a period of one year. To create the tissue microarray and to conduct immunohistochemistry with VE1 antibody melanoma lesion samples were selected.

Results: Ninety-four cases out of 100, were melanoma positive for BRAFV600E detected on immunohistochemistry (IHC) using a monoclonal antibody. The skin was the primary site in seventy-nine (79%) patients, unknown (metastatic) in nineteen and uveal was only in two cases. The diagnostic significance of immunohistochemistry (IHC) for detecting the BRAFV600E mutation in melanoma patients was independent of age, site and stage at diagnosis (p-value <0.05).

Conclusion: Testing of BRAV600E mutation by immunohistochemistry is a rapid, reliable and cost-effective tool in melanoma patients which may further help clinicians in initiating targeted therapy for these patients.